FDA approves Regeneron's Livsayis for generalised myasthenia gravis

The FDA approved Regeneron's Livsayis (cemdisiran) to treat generalised myasthenia gravis in adults with anti-AChR antibodies. The therapy showed significant improvement in clinical trials, with a 4.5-point improvement in daily living scores versus 2.2 for placebo. Regeneron's George Yancopoulos called it a milestone for neurology and siRNA therapy. The EU is reviewing the treatment, with a decision expected in late 2027.

Original reporting
Published Nov 19, 2026, 9:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 10:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$REGN
Relevance
7/10
AlphAI data visualization · based on pharmaceutical-technology.com
Decision brief

The 30-second read

High
01

Why it matters

The approval validates Regeneron's neurology pipeline and may accelerate further RNA‑based product launches.

02

Market read

First FDA‑approved siRNA therapy for a neurological disease, likely to move Regeneron's stock and influence the RNA therapeutic space.

03

What to watch

Reimbursement rates and competition from other myasthenia gravis treatments could temper revenue growth.

Relevance 7/10Novelty 9/10Timing: today

Background

Regeneron partners with Alnylam on the siRNA platform; the drug targets complement component factor 5.

Market effects

Strengthens the biotech/siRNA sector and may boost peers developing RNA therapeutics.

U.S. biotech market gains from a high‑profile FDA approval.

Highlights FDA's openness to RNA therapies, potentially influencing global biotech valuations.

Counterpoint

If the market has already priced in the approval, the stock may see limited upside.

Key entities

  • Regeneron Pharmaceuticals

    US biotech firm developing Livsayis.

  • Alnylam

    Partner in the siRNA technology platform.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.